Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Tao Niu
Institution:
Sarepta Therapeutics (United States)
Observed institutions:
Pfizer (United States),
Sarepta Therapeutics (United States)
ORCID:
0009-0005-7048-0809
Observed ORCID:
0009-0005-7048-0809
OpenAlex ID:
A5115060956
Translational and clinical development of therapeutic siRNA and ASOs: current industry practices, perspectives, and recommendations
2025
·
Jesper Kammersgaard Christensen
, Nicholas Colletti
, et al.
·
Nucleic Acids Research
·
30
PDF
Immunogenicity Risk Assessment for Nucleic Acid Therapeutics: A Comprehensive Evaluation for ASO, siRNA, and Nonvaccine mRNA/LNP Therapies by the IQ Consortium
2025
·
Joanna Grudzinska-Goebel
, Manuela Braun
, et al.
·
Nucleic Acid Therapeutics
·
21
PDF
IQ Survey Results on Current Industry Practices—Part 1: Immunogenicity Risk Assessment
2025
·
Christine Grimaldi
, Susan Richards
, et al.
·
Clinical Pharmacology & Therapeutics
·
6
PDF
IQ Survey Results on Current Industry Practices: Part 2—Quantitative Evaluations of Immunogenicity Assessment
2025
·
Susan Richards
, Insa Winzenborg
, et al.
·
Clinical Pharmacology & Therapeutics
·
4
PDF
Implementing a Bayesian approach using Stan with Torsten: Population pharmacokinetics analysis of somatrogon
2024
·
Yuchen Wang
, Xinyi Pei
, et al.
·
CPT Pharmacometrics & Systems Pharmacology
PDF
Show more works
View as search
Works count:
5
Citation count:
61
H-index:
4
I10-index:
2
Year
Topic
Type
